RE:biotech is slow and coolWE ,THE MARKET, AND PRIVATE SHAREHOLDERS DESERVE AN UPDATE NOW ON THE ANTIAGING TRIAL - why are the trial data statisticians taking more time, they have had approximately 7 weeks already ,so there should be no legitimate reason to delay ,and if there us, then we should be notified.
Yes ,we will be grateful for any deal completion even if years too late ,,especially if they can get any decent upfront payment.
Sglt for cats will not be first to market ,and from my knowledge will take many years of trials even in cats .
Sglt for new human indication would be useful and a potential giant market ,but again several years of clinical trials for TFC molecule that has not passed even phase 1 in any country
The fingers are crossed for a 2023 Abbvie launch and success with TFC 1067
Antivirals 10 years to market if lucky and good follow up testing ,or the follow up testing fails .
we can't keep diluting while waiting ,we shareholders will be even more ultimate bag holders ,so let's see the results now of the main gem potential,otherwise the greatest value residual is the technology and its patents.